The global prevalence of T2DM and obesity continues to increase, creating a major challenge for healthcare systems. Obesity contributes to insulin resistance, chronic inflammation, endothelial dysfunction, and accelerated atherosclerosis, substantially increasing cardiovascular risk in diabetic patients. Traditional diabetes management focused primarily on glycemic control; however, contemporary evidence emphasizes the importance of addressing multiple cardiometabolic risk factors simultaneously. Comprehensive treatment strategies involving endocrinologists, cardiologists, nutritionists, and primary care physicians have demonstrated superior outcomes compared with isolated glycemic management. Therefore, optimization of integrated care remains an important priority in modern diabetology and cardiovascular medicine.
The aim of the study was to evaluate the clinical effectiveness of comprehensive management in patients with T2DM, obesity, and high cardiovascular risk and to assess its impact on metabolic control and cardiovascular risk reduction.
Materials and methods
The study included 120 patients aged 40–75 years diagnosed with T2DM, obesity (body mass index ≥30 kg/m²), and high cardiovascular risk based on established clinical criteria. Baseline assessment included medical history, anthropometric measurements, blood pressure evaluation, electrocardiography, laboratory investigations, glycated hemoglobin (HbA1c), fasting plasma glucose, lipid profile, renal function tests, and cardiovascular risk assessment. The comprehensive management program consisted of individualized nutritional therapy, structured physical activity, weight management counseling, antihyperglycemic therapy, lipid-lowering treatment, antihypertensive therapy, and regular multidisciplinary follow-up over a 12-month period. Statistical analysis was performed to compare baseline and post-treatment clinical parameters.
After 12 months of comprehensive management, significant improvements were observed across multiple clinical indicators. Mean HbA1c levels decreased from 8.7% to 7.1%, while average body weight was reduced by 8.2%. Systolic blood pressure decreased by 14 mmHg and diastolic blood pressure by 8 mmHg. Significant reductions were observed in LDL cholesterol and triglyceride levels, accompanied by improvements in HDL cholesterol concentrations. Patients receiving GLP-1 receptor agonists or SGLT2 inhibitors demonstrated greater weight reduction and improved cardiovascular risk profiles compared with conventional therapy. The overall estimated 10-year cardiovascular risk decreased significantly, and improvements in quality-of-life scores were observed during follow-up.
Comprehensive multidisciplinary management is highly effective for patients with T2DM, obesity, and high cardiovascular risk. Simultaneous control of hyperglycemia, obesity, hypertension, dyslipidemia, and lifestyle factors significantly improves metabolic status and reduces cardiovascular risk. Modern therapeutic strategies incorporating weight-reducing antihyperglycemic agents, aggressive cardiovascular risk factor modification, and structured lifestyle intervention provide superior clinical outcomes. Early implementation of integrated cardiometabolic care may reduce long-term complications and improve survival in this high-risk patient population.
1. American Diabetes Association. Standards of Medical Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1)–S350.
2. Davies M.J., et al. Management of hyperglycemia in type 2 diabetes. Diabetes Care. 2022;45(11):2753–2786.
3. Wilding J.P.H., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
4. Zinman B., et al. Empagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
5. Marso S.P., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
6. Cosentino F., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2023;44(39):4043–4140.
7. Grundy S.M., et al. 2018 AHA/ACC guideline on cholesterol management. Circulation. 2019;139(25)–e1143.
8. Garvey W.T., et al. American Association of Clinical Endocrinology clinical practice guideline for obesity. Endocr Pract. 2022;28(5):528–562.
9. med1.uz – Educational resources and scientific materials on endocrinology and cardiovascular medicine.
10. Eckel R.H., et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care. 2011;34(6):1424–1430.